Last reviewed · How we verify
Cefotan (CEFOTETAN)
Cefotan (CEFOTETAN) is a cephalosporin antibacterial drug developed by a predecessor company and currently owned by B Braun. It targets prostaglandin G/H synthase 2 and is a small molecule modality. Cefotan was FDA approved in 1985 for various bacterial infections, including gonococcal endometritis, Klebsiella pneumoniae infections, and bacteroides infections. The drug is off-patent, with four generic manufacturers available. Key safety considerations include its 4.5-hour half-life.
At a glance
| Generic name | CEFOTETAN |
|---|---|
| Sponsor | B Braun |
| Drug class | Cephalosporin Antibacterial [EPC] |
| Target | Prostaglandin G/H synthase 2 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1985 |
Approved indications
- Acute gonococcal endometritis
- Bacterial infection due to Klebsiella pneumoniae
- Bacterial pneumonia
- Bacterial septicemia
- Bacterial urinary infection
- Bacteroides Endometritis
- Bacteroides Pelvic Inflammatory Disease
- Bacteroides Peritonitis
- Clostridium Peritonitis
- E. Coli Endometritis
- E. Coli Pelvic Inflammatory Disease
- E. Coli Peritonitis
- Endometritis
- Escherichia coli urinary tract infection
- Female genital tract infection
- Fusobacterium Endometritis
- Fusobacterium Pelvic Inflammatory Disease
- Haemophilus influenzae pneumonia
- Infection due to Escherichia coli
- Infection due to Staphylococcus aureus
Common side effects
- Pseudomembranous colitis
- Agranulocytosis
- Hemolytic anemia
- Leukopenia
- Thrombocytopenia
- Prolonged prothrombin time with or without bleeding
- Rise in ALT (SGPT)
- Rise in AST (SGOT)
- Alkaline phosphatase
- Rash
- Itching
- Phlebitis at the site of injection
Key clinical trials
- Cefotetan Therapy for Escherichia Coli Infections (PHASE2)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Effectiveness of Prophylactic Antibiotics Therapy in Laparoscopic Cholecystectomy on Infection Rate (PHASE1)
- A Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039) (PHASE3)
- Arthroscopic Rotator Cuff Repair With Multimodal Analgesia(MMA) (NA)
- Safety and Efficacy of One Dose Prophylactic Antibiotic in Laparoscopic Colorectal Surgery (PHASE2)
- Antibiotics for Postpartum Third and Fourth Degree Perineal Tear Repairs (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |